(Q36675450)

15 August 2017

1 reference

title

Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles (English)

1 reference

15 August 2017

author

Dimitri P Mikhailidis

5

object named as

Dimitri P Mikhailidis

1 reference

15 August 2017

Irene F Gazi

1

1 reference

15 August 2017

Vasilis Tsimihodimos

2

1 reference

15 August 2017

Alexandros D Tselepis

3

1 reference

15 August 2017

Moses Elisaf

4

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 January 2007

1 reference

Expert Opinion on Biological Therapy

15 August 2017

published in

1 reference

15 August 2017

volume

7

1 reference

15 August 2017

issue

1

1 reference

15 August 2017

page(s)

53-72

1 reference

Mortality by cause for eight regions of the world: Global Burden of Disease Study

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Range of serum cholesterol values in the population developing coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Lipoprotein heterogeneity and apolipoprotein B metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Low-Density Lipoprotein Subclass Patterns and Risk of Myocardial Infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

LDL particle size distribution. Results from the Framingham Offspring Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

LDL subclass phenotypes and the insulin resistance syndrome in women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Dietary and genetic probes of atherogenic dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Fasting and postprandial determinants for the occurrence of small dense LDL species in non-insulin-dependent diabetic patients with and without hypertriglyceridaemia: the involvement of insulin, insulin precursor species and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Metabolic origins and clinical significance of LDL heterogeneity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

The role of small, dense low density lipoprotein (LDL): a new look

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Predictors of low-density lipoprotein particle size in a high-risk African-American population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Should we measure routinely the LDL peak particle size?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Clinical relevance of the biochemical, metabolic, and genetic factors that influence low-density lipoprotein heterogeneity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Low-density lipoprotein density and atherosclerosis. Unraveling the connection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Candidate-gene studies of the atherogenic lipoprotein phenotype: a sib-pair linkage analysis of DZ women twins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Genetic epidemiology of low-density lipoprotein subclass phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Inheritance of low density lipoprotein subclass patterns in familial combined hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Pleiotropic genetic effects on LDL size, plasma triglyceride, and HDL cholesterol in families

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Genetics of LDL particle heterogeneity: from genetic epidemiology to DNA-based variations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Dietary and genetic effects on low-density lipoprotein heterogeneity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Smoking diminishes the beneficial effect of statins: observations from the landmark trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Influence of dietary carbohydrate and fat on LDL and HDL particle distributions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Diet-gene interactions in human lipoprotein metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Relationship between low-density lipoprotein size and apolipoprotein A-I-containing particles: the ECTIM study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

CETP gene mutation (D442G) increases low-density lipoprotein particle size in patients with coronary heart disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Linkage of the cholesteryl ester transfer protein (CETP) gene to LDL particle size: use of a novel tetranucleotide repeat within the CETP promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Influence of common variants in the CETP, LPL, HL and APO E genes on LDL heterogeneity in healthy, middle-aged men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Overexpression of lipoprotein lipase in transgenic rabbits leads to increased small dense LDL in plasma and promotes atherosclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

SNP3 polymorphism in apo A-V gene is associated with small dense LDL particles in Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Genotype of the mutant LDL receptor allele is associated with LDL particle size heterogeneity in familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Measurement of small dense low-density lipoprotein particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Measurement of triglyceride-rich lipoproteins by nuclear magnetic resonance spectroscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Measurement issues related to lipoprotein heterogeneity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

A novel and simple method for quantification of small, dense LDL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Clinical significance of small dense low-density lipoprotein cholesterol levels determined by the simple precipitation method

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

LDL-cholesterol/apolipoprotein B ratio is a good predictor of LDL phenotype B in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Assessment of LDL Particle Size by Triglyceride/HDL-Cholesterol Ratio in Non-diabetic,Healthy Subjects without Prominent Hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Transfer of low density lipoprotein into the arterial wall and risk of atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

The atherogenic lipoprotein phenotype and vascular endothelial dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Oxidized LDL and small LDL particle size are independently predictive of a selective defect in microcirculatory endothelial function in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Flow-mediated vasoactivity and circulating adhesion molecules in hypertriglyceridemia: association with small, dense LDL cholesterol particles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Low-density lipoprotein size and cardiovascular risk assessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Low-density lipoprotein particle size is inversely related to plasminogen activator inhibitor-1 levels. The Insulin Resistance Atherosclerosis Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Postprandial lipemia and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

The small, dense LDL phenotype as a correlate of postprandial lipemia in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Composition of human low density lipoprotein: effects of postprandial triglyceride-rich lipoproteins, lipoprotein lipase, hepatic lipase and cholesteryl ester transfer protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Postprandial changes in LDL phenotypes in patients with myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Association between small dense low-density lipoprotein and postprandial accumulation of triglyceride-rich remnant-like particles in normotriglyceridemic patients with myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Clinical relevance of postprandial lipaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Association between LDL particle size and postprandial increase of remnant-like particles in Japanese type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Impact of postprandial variation in triglyceridemia on low-density lipoprotein particle size

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Postprandial lipemia--effect of lipid-lowering drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Increase in aortic pulse wave velocity is associated with abnormal postprandial triglyceride response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Postprandial lipemia in men with metabolic syndrome, hypertensives and healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Postprandial lipemia in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Postprandial lipemia in postmenopausal women with high fasting high-density lipoprotein cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Heterozygote men with familial hypercholesterolaemia may have an abnormal triglyceride response post-prandially. Evidence for another predictor of vascular risk in familial hypercholesterolaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Lipoprotein disorders associated with type 2 diabetes mellitus and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Diabetic dyslipidaemia: insights for optimizing patient management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Pathophysiology of dyslipidaemia in the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Dyslipidaemia, hypercoagulability and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Hypertriglyceridemic hyperapob: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Multiple CHD risk factors in type 2 diabetes: beyond hyperglycaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

What is the consequence of an abnormal lipid profile in patients with type 2 diabetes or the metabolic syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Lipids and lipoproteins in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Atherogenic role of elevated CE transfer from HDL to VLDL(1) and dense LDL in type 2 diabetes : impact of the degree of triglyceridemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Low-density lipoprotein subclass and its correlating factors in diabetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Cardiovascular risk factors and LDL subfraction profile in Type 2 diabetes mellitus subjects with good glycaemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Adverse effects of diabetes on multiple cardiovascular disease risk factors in women. The Strong Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Lipoproteins, apolipoproteins, and low-density lipoprotein size among diabetics in the Framingham offspring study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

LDL-cholesterol, HDL-cholesterol or triglycerides--which is the culprit?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Insulin resistance is not a major determinant of low-density lipoprotein particle size

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

LDL particle size in relation to insulin, proinsulin, and insulin sensitivity. The Insulin Resistance Atherosclerosis Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Insulin resistance and adiposity influence lipoprotein size and subclass concentrations. Results from the Insulin Resistance Atherosclerosis Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Nuclear magnetic resonance lipoprotein abnormalities in prediabetic subjects in the Insulin Resistance Atherosclerosis Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Prevalence of atherosclerotic vascular disease among subjects with the metabolic syndrome with or without diabetes mellitus: the METS-GREECE Multicentre Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Prevention and treatment of the metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Diagnosis and management of the metabolic syndrome in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

The metabolic syndrome, LDL particle size, and atherosclerosis: the Atherosclerosis and Insulin Resistance (AIR) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Low-density lipoprotein particle size, insulin resistance, and proinsulin in a population sample of 58-year-old men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Relationship of LDL size to insulin sensitivity in normoglycemic men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Definitions of metabolic syndrome: Where are we now?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Lipids and lipoprotein subfractions in women with PCOS: relationship to metabolic and endocrine parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Influence of hepatic steatosis (fatty liver) on severity and composition of dyslipidemia in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Small, Dense LDL and Elevated Apolipoprotein B Are the Common Characteristics for the Three Major Lipid Phenotypes of Familial Combined Hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Subclasses of low-density lipoprotein and very low-density lipoprotein in familial combined hyperlipidemia: relationship to multiple lipoprotein phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

The hypertriglyceridemic waist phenotype among women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Hypertriglyceridemic waist: A marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Low adipocyte-derived plasma protein adiponectin concentrations are associated with the metabolic syndrome and small dense low-density lipoprotein particles: atherosclerosis and insulin resistance study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Impact of dyslipidemia in end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Dyslipidemia and renal disease: pathogenesis and clinical consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Uremia-specific alterations in lipid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Ability of non-high-density lipoprotein cholesterol and calculated intermediate-density lipoprotein to identify nontraditional lipoprotein subclass risk factors in dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

The atherogenic lipoprotein phenotype: small dense LDL and lipoprotein remnants in nephrotic range proteinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Elevated levels of small, low-density lipoprotein with high affinity for arterial matrix components in patients with rheumatoid arthritis: possible contribution of phospholipase A2 to this atherogenic profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Cardiovascular risk in systemic lupus erythematosus--evidence of increased oxidative stress and dyslipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Low density lipoprotein particles are small in patients with coronary vasospasm

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Increased small dense LDL and intermediate-density lipoprotein with albuminuria in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

LDL subfractions in acromegaly: relation to growth hormone and insulin-like growth factor-I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Significance of small dense low-density lipoproteins and other risk factors in patients with various types of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Low-density lipoprotein particle size, triglycerides, and high-density lipoprotein cholesterol as risk factors for coronary heart disease in older Japanese-American men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Comparison of various electrophoretic characteristics of LDL particles and their relationship to the risk of ischemic heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Québec Cardiovascular Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Effect of plasma C-reactive protein levels in modulating the risk of coronary heart disease associated with small, dense, low-density lipoproteins in men (The Quebec Cardiovascular Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Significance of small dense low-density lipoprotein-cholesterol concentrations in relation to the severity of coronary heart diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Remarkably high prevalence of small dense low-density lipoprotein in Japanese men with coronary artery disease, irrespective of the presence of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Low-density lipoprotein particle size and coronary atherosclerosis in subjects belonging to hypertensive sibships

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

LDL size and risk of coronary heart disease in elderly men and women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Low density lipoprotein particle size and risk of early-onset myocardial infarction in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Significance of small dense low-density lipoprotein as a risk factor for coronary artery disease and acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Low-density lipoprotein size and subclasses are markers of clinically apparent and non-apparent atherosclerosis in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Does low-density lipoprotein size add to atherogenic particle number in predicting the risk of fatal myocardial infarction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Hypertriglyceridemic hyperapoB in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Québec cardiovascular study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infar

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors: the Ludwigshafen Risk and Cardiovascular Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Predominance of large LDL and reduced HDL2 cholesterol in normolipidemic men with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Relation of LDL size to the insulin resistance syndrome and coronary heart disease in American Indians. The Strong Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Low-density lipoprotein size, pravastatin treatment, and coronary events.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Components of the metabolic syndrome and risk for first-ever acute ischemic nonembolic stroke in elderly subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Risk factors for first-ever acute ischemic non-embolic stroke in elderly individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

LDL particle size distribution is associated with carotid intima-media thickness in healthy 50-year-old men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Relationship between low-density lipoprotein subclasses and asymptomatic atherosclerosis in subjects from the Atherosclerosis Risk in Communities (ARIC) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Association between carotid intima-media thickness and low-density lipoprotein size and susceptibility of low-density lipoprotein to oxidation in asymptomatic members of familial combined hyperlipidemia families

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Small dense low-density lipoprotein and carotid atherosclerosis in relation to vascular dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Lipid levels and peripheral vascular disease in diabetic and non-diabetic subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Increased postprandial lipemia in patients with normolipemic peripheral arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

The clinical relevance of low-density-lipoproteins size modulation by statins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Atorvastatin increases low-density lipoprotein size and enhances high-density lipoprotein cholesterol concentration in male, but not in female patients with familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Effects of Atorvastatin Therapy on the Low-Density Lipoprotein Subfraction, Remnant-Like Particles Cholesterol, and Oxidized Low-Density Lipoprotein Within 2 Weeks in Hypercholesterolemic Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Effects of atorvastatin on electrophoretic characteristics of LDL particles among subjects with heterozygous familial hypercholesterolemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Atorvastatin reduces remnant lipoproteins and small, dense low-density lipoproteins regardless of the baseline lipid pattern

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Effects of atorvastatin on oxidized low-density lipoprotein, low-density lipoprotein subfraction distribution, and remnant lipoprotein in patients with mixed hyperlipoproteinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Effect of statins on LDL particle size in patients with familial combined hyperlipidemia: a comparison between atorvastatin and pravastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Effect of atorvastatin on low-density lipoprotein subtypes in patients with different forms of hyperlipoproteinemia and control subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Effect of atorvastatin on the concentration, relative distribution, and chemical composition of lipoprotein subfractions in patients with dyslipidemias of type IIA and IIB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Effects of atorvastatin on low-density lipoprotein cholesterol phenotype and C-reactive protein levels in patients undergoing long-term dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Once‐Daily Niacin Extended Release/Lovastatin Combination Tablet Has More Favorable Effects on Lipoprotein Particle Size and Subclass Distribution Than Atorvastatin and Simvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Influence of simvastatin on LDL-subtypes in patients with heterozygous familial hypercholesterolemia and in patients with diabetes mellitus and mixed hyperlipoproteinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Effect of simvastatin on the apparent size of LDL particles in patients with type IIB hyperlipoproteinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

The effect of simvastatin on triglyceride-rich lipoproteins in patients with type 2 diabetic dyslipidemia: a SILHOUETTE trial sub-study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Pravastatin treatment in combined hyperlipidaemia. Effect on plasma lipoprotein levels and size

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Effect of pravastatin on LDL particle concentration as determined by NMR spectroscopy: a substudy of a randomized placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Fluvastatin lowers atherogenic dense low-density lipoproteins in postmenopausal women with the atherogenic lipoprotein phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Fluvastatin increases LDL particle size and reduces oxidative stress in patients with hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Fluvastatin improves endothelial dysfunction in overweight postmenopausal women through small dense low-density lipoprotein reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Effect of fluvastatin on low-density lipoprotein peak particle diameter.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Effects of fluvastatin slow-release (XL 80 mg) versus simvastatin (20 mg) on the lipid triad in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Phenotype-dependent and -independent actions of rosuvastatin on atherogenic lipoprotein subfractions in hyperlipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Effect of hypolipidemic drugs on lipoprotein-associated platelet activating factor acetylhydrolase. Implication for atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Effects of antihypertensive and hypolipidemic drugs on plasma and high-density lipoprotein-associated platelet activating factor-acetylhydrolase activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Role of fibric acid derivatives in the management of risk factors for coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Gemfibrozil reduces small low-density lipoprotein more in normolipemic subjects classified as low-density lipoprotein pattern B compared with pattern A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Fenofibrate effectively reduces remnants, and small dense LDL, and increases HDL particle number in hypertriglyceridemic men - a nuclear magnetic resonance study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

A 16-week fenofibrate treatment increases LDL particle size in type IIA dyslipidemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Are high-density lipoprotein and triglyceride levels important in secondary prevention: impressions from the BIP and VA-HIT trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Tr

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Effects of bezafibrate on lipoprotein subclasses and inflammatory markers in patients with hypertriglyceridemia--a nuclear magnetic resonance study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Statin-fibrate combination: therapy for hyperlipidemia: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Effects of extended-release niacin on lipoprotein subclass distribution

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

The use of ezetimibe in achieving low density lipoprotein lowering goals in clinical practice: position statement of a United Kingdom consensus panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

The effects of ezetimibe on the LDL-cholesterol particle number

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

The effect of n-3 fatty acids on low density lipoprotein subfractions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Doxazosin reduces prevalence of small dense low density lipoprotein and remnant-like particle cholesterol levels in nondiabetic and diabetic hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Effect of a low-carbohydrate, ketogenic diet program compared to a low-fat diet on fasting lipoprotein subclasses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Weight loss associated with reduced intake of carbohydrate reduces the atherogenicity of LDL in premenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Effect of plant sterols and endurance training on LDL particle size and distribution in previously sedentary hypercholesterolemic adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Phytosterols in nonfat and low-fat beverages have no impact on the LDL size phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Effect of a nutritional intervention promoting the Mediterranean food pattern on electrophoretic characteristics of low-density lipoprotein particles in healthy women from the Québec City metropolitan area.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Clinical interest of PPARs ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Nonhypoglycemic effects of thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Pioglitazone plus a sulphonylurea or metformin is associated with increased lipoprotein particle size in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Management of co-existing diabetes mellitus and dyslipidemia: defining the role of thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Evidence for a Major Quantitative Trait Locus on Chromosome 17q21 Affecting Low-Density Lipoprotein Peak Particle Diameter

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Tobacco smoking, estrogen receptor α gene variation and small low density lipoprotein level

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

Relationships of low density lipoprotein subfractions to angiographically defined coronary artery disease in young survivors of myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.1.53

21 January 2018

Identifiers

DOI

10.1517/14712598.7.1.53

1 reference

15 August 2017

1 reference